Extended-release niacin proved better than ezetimibe in favorably changing carotid intima-media thickness, a measure of atherosclerosis, in high-risk patients who were already receiving a statin.
Extended-release (ER) niacin proved better than ezetimibe in favorably changing carotid intima-media thickness (CIMT), a measure of atherosclerosis, in high-risk patients who were already receiving a statin, said Allen J. Taylor, MD, at the 2009 scientific sessions of the American Heart Association in Orlando, Fla.
In a study comparing the 2 agents, patients randomly assigned to ER niacin, 2 g/day, achieved a .014 mm regression in CIMT, whereas those assigned to ezetimibe had no evidence of disease regression (P≤.001), said Dr Taylor, a cardiologist at Walter Reed Army Medical Center in Washington, D.C. Paradoxically, those in the ezetimibe group who had the greatest decrease in level of low-density lipoprotein (LDL) cholesterol had increases in CIMT.
A post-hoc analysis showed that although patients in the ezetimibe arm had a significant reduction in LDL cholesterol of an average of 19.2%, to an average of 66 mg/dL, the "greater reductions in LDL cholesterol level in association with ezetimibe were significantly associated with an increase in carotid intima-media thickness," according to Dr Taylor.
Although the study was not powered to detect a difference in the rate of clinical endpoints, the rate of major adverse cardiac events (myocardial infarction, revascularization, cardiovascular death, and hospitalizations for acute coronary syndrome) was significantly lower in the ER niacin arm compared to the ezetimibe arm (1.2% vs 5.5%, respectively; P=.04).
Reliance on a surrogate endpoint such as CIMT to make clinical decisions was a topic of debate, with some experts in cardiovascular medicine saying they preferred data on hard endpoints before reaching a conclusion about the utility of treatments.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.